Second wave already ordering: early adopters have moved from trial to production commitments, and the company is being p
Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that the company's OWN EARLIEST USERS OF A PARTICULAR OFFERING HAVE FINISHED EVALUATING IT AND ARE NOW BUYING IT AS A NORMAL PART OF THEIR OPERATIONS — that is, has the relationship with those first adopters moved from testing, trialing, sampling, qualifying, piloting, or first-time-only purchases into ONGOING, PRODUCTION-LEVEL, OR REPEAT BUYING that is already generating real revenue in the recent period?
Answer YES when management's own words convey, in whatever form fits the business, ONE coherent transition with all three of the following coming through as a present-tense reality:
(1) THERE WAS AN EVALUATION PHASE, AND IT IS OVER FOR AT LEAST SOME ADOPTERS. Management conveys that a specific offering — a product, service, technology, material, format, program, or capability — went through a period in which buyers were trying it, testing it, qualifying it, sampling it, piloting it, or otherwise deciding whether to use it, and that this stage has now been passed by at least some of those buyers. The wording may vary widely: trials converting, pilots graduating, qualification or validation completed, sampling turning into orders, a test site or test line moving into regular use, evaluation units followed by production units, a first season followed by a committed second, or management simply saying the buyers have finished proving it out and moved on to using it.
(2) THOSE SAME BUYERS ARE NOW PURCHASING IN THEIR ORDINARY COURSE, AND IT IS ALREADY BEING PAID FOR. Management points to actual current business from those adopters — repeat or follow-on orders, standing or scheduled purchases, production volumes, ongoing usage, renewals, or regular replenishment — described as happening now in the recent period rather than as expected, promised, or in negotiation. What distinguishes this from ordinary demand is that management ties the current purchasing back to buyers who previously were only testing: the same parties have crossed over.
(3) MOST OF THE BASE OF ADOPTERS, OR MOST OF THEIR USAGE, IS STILL AHEAD. Management conveys, directly or plainly in substance, that this crossing over is early — additional evaluators are still working through their own testing, converted buyers are still ramping toward normal volumes, or the offering is in only a small share of the buyer's operations so far — so the results just reported reflect only the beginning of what the converted and converting base is expected to purchase. Management may express this by describing what remains in trial, how small current volumes are relative to the buyer's full usage, or how it is preparing to serve larger ongoing volumes.
The essence is ONE phenomenon: the risky question of whether buyers would adopt has been answered by buyers themselves through their own money, the answer arrived recently, and the purchasing that follows an affirmative answer has barely started. The industry, the offering, and the form of evaluation may vary widely — industrial qualification, clinical or field trials, retail test placements, software pilots, agricultural trial acreage, sampling programs, first installations, or any comparable path from "we are trying this" to "we buy this."
Answer NO if the offering has always been bought in the ordinary course with no evaluation stage to cross. NO if the buyers are still testing, sampling, piloting, or qualifying, with conversion expected later — an evaluation stage in progress is not this phenomenon. NO if the described conversions are hoped for, projected, in negotiation, or contingent on approvals, funding, or decisions not yet made. NO if management reports strong demand, new customers, or growth generally without connecting current purchasing to buyers who previously were only evaluating. NO if the crossing over is essentially complete and already fully reflected in reported results, with no remaining ramp or remaining evaluators. NO if the only evidence is a single anecdote management itself treats as immaterial. NO if the trial-to-production activity is routine background churn for this business — an ordinary sampling cadence that always converts at the same rate — with no sense that something has changed in the level of business. NO if management is chiefly explaining failed trials, stalled pilots, buyers declining to proceed, or evaluation timelines slipping. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm.
Use only the supplied transcript. Answer only YES or NO.